ID   CLC4K_HUMAN             Reviewed;         328 AA.
AC   Q9UJ71;
DT   21-FEB-2006, integrated into UniProtKB/Swiss-Prot.
DT   24-MAR-2009, sequence version 2.
DT   03-AUG-2022, entry version 170.
DE   RecName: Full=C-type lectin domain family 4 member K;
DE   AltName: Full=Langerin;
DE   AltName: CD_antigen=CD207;
GN   Name=CD207; Synonyms=CLEC4K;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND VARIANT ALA-278.
RX   PubMed=10661407; DOI=10.1016/s1074-7613(00)80160-0;
RA   Valladeau J., Ravel O., Dezutter-Dambuyant C., Moore K., Kleijmeer M.,
RA   Liu Y., Duvert-Frances V., Vincent C., Schmitt D., Davoust J., Caux C.,
RA   Lebecque S., Saeland S.;
RT   "Langerin, a novel C-type lectin specific to Langerhans cells, is an
RT   endocytic receptor that induces the formation of Birbeck granules.";
RL   Immunity 12:71-81(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   SUBUNIT.
RX   PubMed=12626394; DOI=10.1093/glycob/cwg045;
RA   Stambach N.S., Taylor M.E.;
RT   "Characterization of carbohydrate recognition by langerin, a C-type lectin
RT   of Langerhans cells.";
RL   Glycobiology 13:401-410(2003).
RN   [5]
RP   REVIEW.
RX   PubMed=14610287; DOI=10.1385/ir:28:2:93;
RA   Valladeau J., Dezutter-Dambuyant C., Saeland S.;
RT   "Langerin/CD207 sheds light on formation of Birbeck granules and their
RT   possible function in Langerhans cells.";
RL   Immunol. Res. 28:93-107(2003).
RN   [6]
RP   FUNCTION.
RX   PubMed=17334373; DOI=10.1038/nm1541;
RA   de Witte L., Nabatov A., Pion M., Fluitsma D., de Jong M.A., de Gruijl T.,
RA   Piguet V., van Kooyk Y., Geijtenbeek T.B.;
RT   "Langerin is a natural barrier to HIV-1 transmission by Langerhans cells.";
RL   Nat. Med. 13:367-371(2007).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, DOMAIN C-TYPE LECTIN, AND MUTAGENESIS OF
RP   GLU-285; ASN-287; LYS-299 AND LYS-313.
RX   PubMed=20026605; DOI=10.1074/jbc.m109.041863;
RA   Tateno H., Ohnishi K., Yabe R., Hayatsu N., Sato T., Takeya M.,
RA   Narimatsu H., Hirabayashi J.;
RT   "Dual specificity of langerin to sulfated and mannosylated glycans via a
RT   single C-type carbohydrate recognition domain.";
RL   J. Biol. Chem. 285:6390-6400(2010).
RN   [9]
RP   FUNCTION.
RX   PubMed=20097424; DOI=10.1016/j.molimm.2009.12.016;
RA   de Jong M.A., Vriend L.E., Theelen B., Taylor M.E., Fluitsma D.,
RA   Boekhout T., Geijtenbeek T.B.;
RT   "C-type lectin Langerin is a beta-glucan receptor on human Langerhans cells
RT   that recognizes opportunistic and pathogenic fungi.";
RL   Mol. Immunol. 47:1216-1225(2010).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 188-328, AND DISULFIDE BONDS.
RX   PubMed=19175323; DOI=10.1021/bi802151w;
RA   Thepaut M., Valladeau J., Nurisso A., Kahn R., Arnou B., Vives C.,
RA   Saeland S., Ebel C., Monnier C., Dezutter-Dambuyant C., Imberty A.,
RA   Fieschi F.;
RT   "Structural studies of langerin and Birbeck granule: a macromolecular
RT   organization model.";
RL   Biochemistry 48:2684-2698(2009).
RN   [11]
RP   VARIANT BIRGD ARG-264.
RX   PubMed=15816828; DOI=10.1111/j.0022-202x.2005.23645.x;
RA   Verdijk P., Dijkman R., Plasmeijer E.I., Mulder A.A., Zoutman W.H.,
RA   Mieke Mommaas A., Tensen C.P.;
RT   "A lack of Birbeck granules in Langerhans cells is associated with a
RT   naturally occurring point mutation in the human Langerin gene.";
RL   J. Invest. Dermatol. 124:714-717(2005).
RN   [12]
RP   VARIANTS ALA-278; ASP-288 AND PRO-300, CHARACTERIZATION OF VARIANT BIRGD
RP   ARG-264, AND CHARACTERIZATION OF VARIANTS ALA-278; ASP-288 AND PRO-300.
RX   PubMed=16567809; DOI=10.1074/jbc.m511502200;
RA   Ward E.M., Stambach N.S., Drickamer K., Taylor M.E.;
RT   "Polymorphisms in human langerin affect stability and sugar binding
RT   activity.";
RL   J. Biol. Chem. 281:15450-15456(2006).
CC   -!- FUNCTION: Calcium-dependent lectin displaying mannose-binding
CC       specificity. Induces the formation of Birbeck granules (BGs); is a
CC       potent regulator of membrane superimposition and zippering. Binds to
CC       sulfated as well as mannosylated glycans, keratan sulfate (KS) and
CC       beta-glucans. Facilitates uptake of antigens and is involved in the
CC       routing and/or processing of antigen for presentation to T cells. Major
CC       receptor on primary Langerhans cells for Candida species, Saccharomyces
CC       species, and Malassezia furfur. Protects against human immunodeficiency
CC       virus-1 (HIV-1) infection. Binds to high-mannose structures present on
CC       the envelope glycoprotein which is followed by subsequent targeting of
CC       the virus to the Birbeck granules leading to its rapid degradation.
CC       {ECO:0000269|PubMed:10661407, ECO:0000269|PubMed:17334373,
CC       ECO:0000269|PubMed:20026605, ECO:0000269|PubMed:20097424}.
CC   -!- SUBUNIT: Homotrimer. {ECO:0000269|PubMed:12626394}.
CC   -!- INTERACTION:
CC       Q9UJ71; O43889-2: CREB3; NbExp=3; IntAct=EBI-2873235, EBI-625022;
CC       Q9UJ71; Q9Y282: ERGIC3; NbExp=3; IntAct=EBI-2873235, EBI-781551;
CC       Q9UJ71; Q96HH9: GRAMD2B; NbExp=6; IntAct=EBI-2873235, EBI-2832937;
CC       Q9UJ71; O00767: SCD; NbExp=3; IntAct=EBI-2873235, EBI-2684237;
CC       Q9UJ71; Q96IW7: SEC22A; NbExp=3; IntAct=EBI-2873235, EBI-8652744;
CC       Q9UJ71; Q6PEW1: ZCCHC12; NbExp=3; IntAct=EBI-2873235, EBI-748373;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:10661407}; Single-
CC       pass type II membrane protein {ECO:0000269|PubMed:10661407}. Note=Found
CC       in Birbeck granules (BGs), which are organelles consisting of
CC       superimposed and zippered membranes.
CC   -!- TISSUE SPECIFICITY: Exclusively expressed by Langerhans cells.
CC       Expressed in astrocytoma and malignant ependymoma, but not in normal
CC       brain tissues. {ECO:0000269|PubMed:10661407,
CC       ECO:0000269|PubMed:20026605}.
CC   -!- DOMAIN: The C-type lectin domain mediates dual recognition of both
CC       sulfated and mannosylated glycans. {ECO:0000269|PubMed:20026605}.
CC   -!- DISEASE: Birbeck granule deficiency (BIRGD) [MIM:613393]: A condition
CC       characterized by the absence of Birbeck granules in epidermal
CC       Langerhans cells. Despite the lack of Birbeck granules, Langerhans
CC       cells are present in normal numbers and have normal morphologic
CC       characteristics and antigen-presenting capacity.
CC       {ECO:0000269|PubMed:15816828, ECO:0000269|PubMed:16567809}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Langerin;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Ctlect_00126";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ242859; CAB62403.1; -; mRNA.
DR   EMBL; AC007395; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC022278; AAH22278.1; -; mRNA.
DR   CCDS; CCDS74520.1; -.
DR   RefSeq; NP_056532.4; NM_015717.4.
DR   RefSeq; XP_011531176.1; XM_011532874.1.
DR   PDB; 3C22; X-ray; 1.50 A; A/B/C/D=188-328.
DR   PDB; 3KQG; X-ray; 2.30 A; A/B/C/D/E/F=147-328.
DR   PDB; 3P5D; X-ray; 1.80 A; A/B/C/D=193-328.
DR   PDB; 3P5E; X-ray; 1.70 A; A/B/C/D=193-328.
DR   PDB; 3P5F; X-ray; 1.75 A; A/B/C/D=193-328.
DR   PDB; 3P5G; X-ray; 1.60 A; A/B/C/D=193-328.
DR   PDB; 3P5H; X-ray; 1.61 A; A/B/C/D=193-328.
DR   PDB; 3P5I; X-ray; 1.80 A; A/B/C/D=193-328.
DR   PDB; 3P7F; X-ray; 2.50 A; A/B/C/D=193-328.
DR   PDB; 3P7G; X-ray; 1.60 A; A/B/C/D=193-328.
DR   PDB; 3P7H; X-ray; 2.30 A; A/B/C/D=193-328.
DR   PDB; 4AK8; X-ray; 1.40 A; A/B/C/D=188-328.
DR   PDB; 4N32; X-ray; 1.75 A; A/B/C/D=193-328.
DR   PDB; 4N33; X-ray; 1.85 A; A/B/C/D=193-328.
DR   PDB; 4N34; X-ray; 1.75 A; A/B/C/D=193-328.
DR   PDB; 4N35; X-ray; 1.85 A; A/B/C/D=193-328.
DR   PDB; 4N36; X-ray; 1.85 A; A/B/C/D=193-328.
DR   PDB; 4N37; X-ray; 2.00 A; A/B/C/D=193-328.
DR   PDB; 4N38; X-ray; 2.00 A; A/B/C/D=193-328.
DR   PDB; 5G6U; X-ray; 1.84 A; A/B/C/D=68-328.
DR   PDBsum; 3C22; -.
DR   PDBsum; 3KQG; -.
DR   PDBsum; 3P5D; -.
DR   PDBsum; 3P5E; -.
DR   PDBsum; 3P5F; -.
DR   PDBsum; 3P5G; -.
DR   PDBsum; 3P5H; -.
DR   PDBsum; 3P5I; -.
DR   PDBsum; 3P7F; -.
DR   PDBsum; 3P7G; -.
DR   PDBsum; 3P7H; -.
DR   PDBsum; 4AK8; -.
DR   PDBsum; 4N32; -.
DR   PDBsum; 4N33; -.
DR   PDBsum; 4N34; -.
DR   PDBsum; 4N35; -.
DR   PDBsum; 4N36; -.
DR   PDBsum; 4N37; -.
DR   PDBsum; 4N38; -.
DR   PDBsum; 5G6U; -.
DR   AlphaFoldDB; Q9UJ71; -.
DR   SMR; Q9UJ71; -.
DR   BioGRID; 119076; 25.
DR   IntAct; Q9UJ71; 13.
DR   STRING; 9606.ENSP00000386378; -.
DR   BindingDB; Q9UJ71; -.
DR   ChEMBL; CHEMBL2176853; -.
DR   UniLectin; Q9UJ71; -.
DR   GlyGen; Q9UJ71; 3 sites.
DR   iPTMnet; Q9UJ71; -.
DR   PhosphoSitePlus; Q9UJ71; -.
DR   BioMuta; CD207; -.
DR   DMDM; 229784129; -.
DR   jPOST; Q9UJ71; -.
DR   MassIVE; Q9UJ71; -.
DR   PaxDb; Q9UJ71; -.
DR   PeptideAtlas; Q9UJ71; -.
DR   PRIDE; Q9UJ71; -.
DR   ProteomicsDB; 84594; -.
DR   Antibodypedia; 2366; 504 antibodies from 36 providers.
DR   DNASU; 50489; -.
DR   Ensembl; ENST00000410009.5; ENSP00000386378.3; ENSG00000116031.9.
DR   GeneID; 50489; -.
DR   KEGG; hsa:50489; -.
DR   MANE-Select; ENST00000410009.5; ENSP00000386378.3; NM_015717.5; NP_056532.4.
DR   UCSC; uc002shg.4; human.
DR   CTD; 50489; -.
DR   DisGeNET; 50489; -.
DR   GeneCards; CD207; -.
DR   HGNC; HGNC:17935; CD207.
DR   HPA; ENSG00000116031; Tissue enriched (skin).
DR   MalaCards; CD207; -.
DR   MIM; 604862; gene.
DR   MIM; 613393; phenotype.
DR   neXtProt; NX_Q9UJ71; -.
DR   OpenTargets; ENSG00000116031; -.
DR   PharmGKB; PA134986203; -.
DR   VEuPathDB; HostDB:ENSG00000116031; -.
DR   eggNOG; KOG4297; Eukaryota.
DR   GeneTree; ENSGT00940000161863; -.
DR   HOGENOM; CLU_081746_0_0_1; -.
DR   InParanoid; Q9UJ71; -.
DR   OMA; QFCVSRN; -.
DR   OrthoDB; 988771at2759; -.
DR   PhylomeDB; Q9UJ71; -.
DR   TreeFam; TF333341; -.
DR   PathwayCommons; Q9UJ71; -.
DR   Reactome; R-HSA-1236978; Cross-presentation of soluble exogenous antigens (endosomes).
DR   SignaLink; Q9UJ71; -.
DR   BioGRID-ORCS; 50489; 9 hits in 318 CRISPR screens.
DR   EvolutionaryTrace; Q9UJ71; -.
DR   GeneWiki; Langerin; -.
DR   GenomeRNAi; 50489; -.
DR   Pharos; Q9UJ71; Tbio.
DR   PRO; PR:Q9UJ71; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9UJ71; protein.
DR   Bgee; ENSG00000116031; Expressed in upper leg skin and 87 other tissues.
DR   Genevisible; Q9UJ71; HS.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0030139; C:endocytic vesicle; TAS:ProtInc.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030246; F:carbohydrate binding; IDA:UniProtKB.
DR   GO; GO:0005537; F:mannose binding; TAS:ProtInc.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   CDD; cd03590; CLECT_DC-SIGN_like; 1.
DR   Gene3D; 3.10.100.10; -; 1.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR018378; C-type_lectin_CS.
DR   InterPro; IPR033989; CD209-like_CTLD.
DR   InterPro; IPR016187; CTDL_fold.
DR   Pfam; PF00059; Lectin_C; 1.
DR   SMART; SM00034; CLECT; 1.
DR   SUPFAM; SSF56436; SSF56436; 1.
DR   PROSITE; PS00615; C_TYPE_LECTIN_1; 1.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Disulfide bond; Glycoprotein; Lectin; Membrane;
KW   Reference proteome; Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN           1..328
FT                   /note="C-type lectin domain family 4 member K"
FT                   /id="PRO_0000223693"
FT   TOPO_DOM        1..43
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        44..64
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        65..328
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          202..320
FT                   /note="C-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   COILED          145..190
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        87
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        113
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        180
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        223..319
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040,
FT                   ECO:0000269|PubMed:19175323"
FT   DISULFID        295..311
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040,
FT                   ECO:0000269|PubMed:19175323"
FT   VARIANT         55
FT                   /note="A -> V (in dbSNP:rs10489990)"
FT                   /id="VAR_054781"
FT   VARIANT         136
FT                   /note="Q -> E (in dbSNP:rs17718987)"
FT                   /id="VAR_056151"
FT   VARIANT         213
FT                   /note="P -> S (in dbSNP:rs17006436)"
FT                   /id="VAR_054782"
FT   VARIANT         264
FT                   /note="W -> R (in BIRGD; abolishes mannose-binding ability;
FT                   dbSNP:rs200837270)"
FT                   /evidence="ECO:0000269|PubMed:15816828,
FT                   ECO:0000269|PubMed:16567809"
FT                   /id="VAR_063828"
FT   VARIANT         278
FT                   /note="V -> A (no effect on mannose-binding ability;
FT                   dbSNP:rs741326)"
FT                   /evidence="ECO:0000269|PubMed:10661407,
FT                   ECO:0000269|PubMed:16567809"
FT                   /id="VAR_054783"
FT   VARIANT         288
FT                   /note="N -> D (significant reduction in mannose-binding
FT                   ability; dbSNP:rs13383830)"
FT                   /evidence="ECO:0000269|PubMed:16567809"
FT                   /id="VAR_054784"
FT   VARIANT         300
FT                   /note="A -> P (significant reduction in mannose-binding
FT                   ability; significant decrease in thermal stability;
FT                   increased sensitivity of sugar binding to pH change;
FT                   dbSNP:rs2080391)"
FT                   /evidence="ECO:0000269|PubMed:16567809"
FT                   /id="VAR_059448"
FT   MUTAGEN         285
FT                   /note="E->A: Loss of binding to 6'-sulfo-LacNAc and
FT                   invertase."
FT                   /evidence="ECO:0000269|PubMed:20026605"
FT   MUTAGEN         287
FT                   /note="N->A: Loss of binding to 6'-sulfo-LacNAc and
FT                   invertase."
FT                   /evidence="ECO:0000269|PubMed:20026605"
FT   MUTAGEN         299
FT                   /note="K->A: Loss of binding to 6'-sulfo-LacNAc."
FT                   /evidence="ECO:0000269|PubMed:20026605"
FT   MUTAGEN         313
FT                   /note="K->A: Loss of binding to 6'-sulfo-LacNAc and
FT                   6-sulfo-GlcNAc."
FT                   /evidence="ECO:0000269|PubMed:20026605"
FT   HELIX           160..195
FT                   /evidence="ECO:0007829|PDB:3KQG"
FT   TURN            196..198
FT                   /evidence="ECO:0007829|PDB:3KQG"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   STRAND          205..209
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   HELIX           216..225
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   HELIX           236..246
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   STRAND          251..258
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   TURN            259..262
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   STRAND          263..266
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   HELIX           274..277
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   HELIX           278..280
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   HELIX           289..291
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   STRAND          295..298
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   STRAND          300..304
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   STRAND          306..309
FT                   /evidence="ECO:0007829|PDB:4AK8"
FT   STRAND          315..322
FT                   /evidence="ECO:0007829|PDB:4AK8"
SQ   SEQUENCE   328 AA;  36725 MW;  83DF432682BF4B62 CRC64;
     MTVEKEAPDA HFTVDKQNIS LWPREPPPKS GPSLVPGKTP TVRAALICLT LVLVASVLLQ
     AVLYPRFMGT ISDVKTNVQL LKGRVDNIST LDSEIKKNSD GMEAAGVQIQ MVNESLGYVR
     SQFLKLKTSV EKANAQIQIL TRSWEEVSTL NAQIPELKSD LEKASALNTK IRALQGSLEN
     MSKLLKRQND ILQVVSQGWK YFKGNFYYFS LIPKTWYSAE QFCVSRNSHL TSVTSESEQE
     FLYKTAGGLI YWIGLTKAGM EGDWSWVDDT PFNKVQSVRF WIPGEPNNAG NNEHCGNIKA
     PSLQAWNDAP CDKTFLFICK RPYVPSEP
//
